Becton, Dickinson and Company - US Medtechwert (Seite 3)
eröffnet am 10.09.08 13:38:39 von
neuester Beitrag 28.11.23 05:19:19 von
neuester Beitrag 28.11.23 05:19:19 von
Beiträge: 44
ID: 1.144.119
ID: 1.144.119
Aufrufe heute: 0
Gesamt: 7.669
Gesamt: 7.669
Aktive User: 0
ISIN: US0758871091 · WKN: 857675 · Symbol: BOX
214,10
EUR
-0,37 %
-0,80 EUR
Letzter Kurs 09:04:10 Tradegate
Neuigkeiten
Werte aus der Branche Gesundheitswesen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5500 | +33,50 | |
| 1,6240 | +29,71 | |
| 19,44 | +27,22 | |
| 1,6600 | +23,88 | |
| 8,0000 | +20,30 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 57,50 | -12,21 | |
| 7,4500 | -13,37 | |
| 1,4400 | -14,79 | |
| 3,8900 | -15,07 | |
| 0,5925 | -15,36 |
Beitrag zu dieser Diskussion schreiben
Feedback
Habe mir soeben ein paar Anteilsscheine ins Depot gelegt und freue mich über einen Kaufkurs von 116,50€.
Mit der aktuellen Bewertung kann ich leben und auf Sicht von einigen Jahren erhoffe ich mir einen guten Einstiegskurs. Wenn noch weiter runter geht, werde ich mich aber auch nicht grämen....
Mit der aktuellen Bewertung kann ich leben und auf Sicht von einigen Jahren erhoffe ich mir einen guten Einstiegskurs. Wenn noch weiter runter geht, werde ich mich aber auch nicht grämen....
Antwort auf Beitrag Nr.: 51.531.000 von Larry.Livingston am 19.01.16 20:00:43Medizintechniker BD erhöht die Dividende das 44. Jahr in Folge
Der amerikanische Medizintechniker Becton, Dickinson and Company steigert seine Quartalsdividende um zehn Prozent auf 66 US-Cents. Damit erhalten die Aktionäre auf das Gesamtjahr gerechnet künftig 2,64 US-Dollar. Die Dividendenrendite liegt beim aktuellen Börsenkurs von 150,92 US-Dollar (Stand: 23. November 2015) bei 1,75 Prozent.
Ausgeschüttet wird die Dividende am 31. Dezember 2015 (Record day: 10. Dezember 2015). Mit der jetzigen Steigerung hat der Konzern die Dividende das 43. Jahr in ununterbrochener Folge erhöht. Damit zählt Becton Dickinson zu den Dividendenaristokraten – das sind Unternehmen, die seit mindestens 25 Jahren die Dividende jedes Jahr erhöhen.
Becton Dickinson And Company ist ein amerikanisches Medizintechnik-Unternehmen. Das Unternehmen wurde 1897 gegründet und hat seinen Firmensitz in Franklin Lakes im US-Bundesstaat New Jersey. Zu den Produkten zählen medizinische Einmalartikel, Gerätesysteme und Reagenzien. Zuletzt wurde mit 45.000 Mitarbeitern ein Umsatz von 10,3 Mrd. US-Dollar bei einem Betriebsgewinn (EBIT) von 1,5 Mrd. US-Dollar erwirtschaftet.
Quelle: MyDividends.de
Der amerikanische Medizintechniker Becton, Dickinson and Company steigert seine Quartalsdividende um zehn Prozent auf 66 US-Cents. Damit erhalten die Aktionäre auf das Gesamtjahr gerechnet künftig 2,64 US-Dollar. Die Dividendenrendite liegt beim aktuellen Börsenkurs von 150,92 US-Dollar (Stand: 23. November 2015) bei 1,75 Prozent.
Ausgeschüttet wird die Dividende am 31. Dezember 2015 (Record day: 10. Dezember 2015). Mit der jetzigen Steigerung hat der Konzern die Dividende das 43. Jahr in ununterbrochener Folge erhöht. Damit zählt Becton Dickinson zu den Dividendenaristokraten – das sind Unternehmen, die seit mindestens 25 Jahren die Dividende jedes Jahr erhöhen.
Becton Dickinson And Company ist ein amerikanisches Medizintechnik-Unternehmen. Das Unternehmen wurde 1897 gegründet und hat seinen Firmensitz in Franklin Lakes im US-Bundesstaat New Jersey. Zu den Produkten zählen medizinische Einmalartikel, Gerätesysteme und Reagenzien. Zuletzt wurde mit 45.000 Mitarbeitern ein Umsatz von 10,3 Mrd. US-Dollar bei einem Betriebsgewinn (EBIT) von 1,5 Mrd. US-Dollar erwirtschaftet.
Quelle: MyDividends.de
Antwort auf Beitrag Nr.: 51.531.000 von Larry.Livingston am 19.01.16 20:00:43Seit dem letzten Posting von space Ende 2008 hat sich einiges getan. Ich werde mal versuchen, deine Erinnerung und die aller Anderen ein wenig auffrischen. 
2008 hatte BDX ein eps von 4,461$, 2015 waren es 3,35$. Das klingt erstmal ernüchternd, hat aber mit der Akquisition von CareFuison zu tun. (Darauf werde ich gesondert eingehen.)
Die gesamte eps-reihe der letzten Jahre lautet (Quelle morningstar):
2011: 5,62$, 2012 5,59$, 2013: 6,49$, 2014: 5,99$ 2015: 3,35$
Für 2016 wird dann laut 4-traders ein Sprung auf 7,95$ erwartet, 2017 sollen es bereits 9,02$ sein und in 2018 9,91.
Die Dividendenrendite liegt zwar bei unter 2%, allerdings wird die Ausschüttung permanent gesteigert. (siehe Folgebeitrag).
2008 hatte BDX ein eps von 4,461$, 2015 waren es 3,35$. Das klingt erstmal ernüchternd, hat aber mit der Akquisition von CareFuison zu tun. (Darauf werde ich gesondert eingehen.)
Die gesamte eps-reihe der letzten Jahre lautet (Quelle morningstar):
2011: 5,62$, 2012 5,59$, 2013: 6,49$, 2014: 5,99$ 2015: 3,35$
Für 2016 wird dann laut 4-traders ein Sprung auf 7,95$ erwartet, 2017 sollen es bereits 9,02$ sein und in 2018 9,91.
Die Dividendenrendite liegt zwar bei unter 2%, allerdings wird die Ausschüttung permanent gesteigert. (siehe Folgebeitrag).
Danke für den Reminder, ganz vergessen das die auch noch in meinem Depot schlummern...
Antwort auf Beitrag Nr.: 51.528.708 von CommunitySupport am 19.01.16 15:56:33Vielen Dank für die Wiederbelebung!
Nachdem BDX seit geraumer Zeit auf meiner Watchlist weilt, fand ich, dass sie (wieder) einen eigenen Thread verdient haben.
Auch wenn von Anfang an gemutmaßt wurde, dass BDX nicht zu den w:o Lieblingen werde würde (ist aber evtl. auch besser) so will ich nun versuchen, diesen Diskussionsstrang am Leben zu halten.
Und wenn ich mir die bisherigen Postings anschaue, handelt es sich eindeutig um die üblichen Verdächtigen.
Viele Grüße
1435905
Nachdem BDX seit geraumer Zeit auf meiner Watchlist weilt, fand ich, dass sie (wieder) einen eigenen Thread verdient haben.
Auch wenn von Anfang an gemutmaßt wurde, dass BDX nicht zu den w:o Lieblingen werde würde (ist aber evtl. auch besser) so will ich nun versuchen, diesen Diskussionsstrang am Leben zu halten.
Und wenn ich mir die bisherigen Postings anschaue, handelt es sich eindeutig um die üblichen Verdächtigen.
Viele Grüße
1435905
Trading Spotlight
Liebe Diskussionsteilnehmer,
in diesem Thread kann jetzt wieder geschrieben werden.
Viel Spaß!
in diesem Thread kann jetzt wieder geschrieben werden.
Viel Spaß!
und da sind sie:
Becton Dickinson outlook falls short of forecasts
Wednesday November 5, 7:51 am ET
Becton Dickinson expects profit and revenue boost, but outlook misses forecasts
FRANKLIN LAKES, N.J. (AP) -- Medical-device maker Becton Dickinson and Co. said Wednesday it expects profit and revenue boosts in fiscal 2009, but the guidance falls short of Wall Street expectations.
ADVERTISEMENT
Becton Dickinson said a stronger dollar is expected to damp currency exchange benefits from global sales. The company gets the majority of its revenue from overseas.
Operating margin improvement, however, is expected to offset that drag, it added.
Becton Dickinson expects earnings per share to rise between 8 percent and 10 percent from $4.46 per share in the year just ended Sept. 30. That suggests the company expects profit of between $4.82 per share and $4.91 per share.
Analysts polled by Thomson Reuters expect fiscal 2009 profit of $4.91 per share.
Becton Dickinson said it expects revenue will increase 1 percent to 2 percent from revenue of $7.16 billion in fiscal 2008. That means the company would post revenue of between $7.23 billion and $7.30 billion next September, falling short of analyst forecasts for $7.55 billion in revenue.
Becton Dickinson outlook falls short of forecasts
Wednesday November 5, 7:51 am ET
Becton Dickinson expects profit and revenue boost, but outlook misses forecasts
FRANKLIN LAKES, N.J. (AP) -- Medical-device maker Becton Dickinson and Co. said Wednesday it expects profit and revenue boosts in fiscal 2009, but the guidance falls short of Wall Street expectations.
ADVERTISEMENT
Becton Dickinson said a stronger dollar is expected to damp currency exchange benefits from global sales. The company gets the majority of its revenue from overseas.
Operating margin improvement, however, is expected to offset that drag, it added.
Becton Dickinson expects earnings per share to rise between 8 percent and 10 percent from $4.46 per share in the year just ended Sept. 30. That suggests the company expects profit of between $4.82 per share and $4.91 per share.
Analysts polled by Thomson Reuters expect fiscal 2009 profit of $4.91 per share.
Becton Dickinson said it expects revenue will increase 1 percent to 2 percent from revenue of $7.16 billion in fiscal 2008. That means the company would post revenue of between $7.23 billion and $7.30 billion next September, falling short of analyst forecasts for $7.55 billion in revenue.
heute kommen zahlen vorbörslich:
Earnings Preview: Becton, Dickinson
by: theflyonthewall.com November 04, 2008 | about stocks: BDX
TheFlyOnTheWall
Becton, Dickinson and Co. (BDX) is expected to report Q4 earnings before market open Wednesday Nov. 4, with conference call scheduled for 10:00 am EST.
Guidance
Analysts are expecting a profit of $1.11 on revenue of $1.81B. The consensus range for EPS is $1.10 to $1.14 with a revenue range of $1.79B to $1.84B, according to First Call. For Q3, the company reported EPS $1.18 verses consensus of $1.10 and revenue $1.87B verses consensus of $1.79B.
Analyst Views
Positive drivers this quarter include growth in Advate sales and antibody therapies. Negative drivers this quarter include slowing growth in the medication delivery division and sales declines in the injectables division. On September 19, Banc of America initiated the shares with a Buy and a price target of $92.
Earnings Preview: Becton, Dickinson
by: theflyonthewall.com November 04, 2008 | about stocks: BDX
TheFlyOnTheWall
Becton, Dickinson and Co. (BDX) is expected to report Q4 earnings before market open Wednesday Nov. 4, with conference call scheduled for 10:00 am EST.
Guidance
Analysts are expecting a profit of $1.11 on revenue of $1.81B. The consensus range for EPS is $1.10 to $1.14 with a revenue range of $1.79B to $1.84B, according to First Call. For Q3, the company reported EPS $1.18 verses consensus of $1.10 and revenue $1.87B verses consensus of $1.79B.
Analyst Views
Positive drivers this quarter include growth in Advate sales and antibody therapies. Negative drivers this quarter include slowing growth in the medication delivery division and sales declines in the injectables division. On September 19, Banc of America initiated the shares with a Buy and a price target of $92.
nachbörslich kam diese Höherstufung:
http://www.zacks.com/blog/post_detail.html?t=15405
Becton, Dickinson Upped to Buy
Posted Tue Oct 21, 04:57 pm ET
Posted By: Christopher Titus, CFA
Becton, Dickinson (BDX) operates three business segments that provide disposable/consumable products to the medical community. We believe the majority of these product markets should remain relatively insulated from the current economic turmoil.
The company's focus on safety-engineered products has gained momentum as healthcare providers seek to reduce hospital-acquired infections and governments require tighter operating standards. This has provided Becton, Dickinson with a strong position in the industry.
At the current price, shares of Becton, Dickinson trades at 16.2x our fiscal year 2008 estimate of $4.45, a discount to the average 16.7x 2008 multiple of medical supply peers and roughly a 20% discount to the group average 1.5x 2008 P/E/G. We believe this name should trade inline with the group and are raising our valuation to a 1.5x 2008 P/E/G.
This brings our target price to $85.50, providing investors with an expected potential ne
http://www.zacks.com/blog/post_detail.html?t=15405
Becton, Dickinson Upped to Buy
Posted Tue Oct 21, 04:57 pm ET
Posted By: Christopher Titus, CFA
Becton, Dickinson (BDX) operates three business segments that provide disposable/consumable products to the medical community. We believe the majority of these product markets should remain relatively insulated from the current economic turmoil.
The company's focus on safety-engineered products has gained momentum as healthcare providers seek to reduce hospital-acquired infections and governments require tighter operating standards. This has provided Becton, Dickinson with a strong position in the industry.
At the current price, shares of Becton, Dickinson trades at 16.2x our fiscal year 2008 estimate of $4.45, a discount to the average 16.7x 2008 multiple of medical supply peers and roughly a 20% discount to the group average 1.5x 2008 P/E/G. We believe this name should trade inline with the group and are raising our valuation to a 1.5x 2008 P/E/G.
This brings our target price to $85.50, providing investors with an expected potential ne
Hallo,
so, konnte heute nicht widerstehen, mir ein paar BDXe ins Depot zu legen nach dem Rückschlag. Hier noch ein interessantes statement von Herrn CRAMER:
Buy Becton Dickinson?
Posted By:Tom Brennan
Topics:Commodities | Stock Picks | Stock Market
Sectors:Health Care | Health Care Equipment and Services | Oil and Gas
Companies:Becton Dickinson and Co
A lot of companies, until very recently, were watching their margins shrink thanks to surging commodity costs. But now that those costs have come down, a number of firms are on track to regain their lost profits. Cramer’s been looking for stocks that not only benefit from this trend but also work in a recession. Because if the talk is true, that’s just where we’re headed.
Becton Dickinson [BDX 73.31 0.95 (+1.31%) ] makes medical equipment from syringes and needles to infection systems and lab analyzers, just the type of equipment hospitals need regardless of record declines on the Dow. And BDX uses oil-based resin to make many of its products, an expense that jumped $20 million from 2007 to 2008. Back before the commodity decline, the company expected resin costs to jump another $20 million through 2009 based on $125 oil. But now that the price per barrel is down to $74, BDX could net more profit than expected, and that might send the stock higher.
This is a longer-term play, though. The lower costs won’t reach BDX’s bottom line for three to five months because at last report the company had three to four months worth of resin inventory. So think of BDX for 2009. Cramer did say, though, that the change in costs might mean an increase in 2009 guidance when BDX reports its fiscal fourth quarter on Nov. 5.
And Cramer expects good numbers from that report – the company’s beaten earnings every quarter for over a year. BDX is a seller of staple medical supplies, and it’s a market leader in most of the products it sells. So overall this is a consistent performer no matter which direction the market’s headed, and the lower costs make it even more attractive.
While price-to-earnings multiples haven’t worked for a lot of stocks in this market – who can trust projected earnings right now? – PEs do work for names not so sensitive to the economy. So BDX 14.4 multiple on next year’s conservative earnings estimate of $4.93 a share (remember: analysts are concerned about costs) can be trusted.
Given that BDX is the type of stock investors flock to in a downturn, Cramer said it’s not unlikely that multiple could climb to 18 during a recession. If that happens, then next year BDX will be worth $89, a 23% jump from present levels.
so, konnte heute nicht widerstehen, mir ein paar BDXe ins Depot zu legen nach dem Rückschlag. Hier noch ein interessantes statement von Herrn CRAMER:
Buy Becton Dickinson?
Posted By:Tom Brennan
Topics:Commodities | Stock Picks | Stock Market
Sectors:Health Care | Health Care Equipment and Services | Oil and Gas
Companies:Becton Dickinson and Co
A lot of companies, until very recently, were watching their margins shrink thanks to surging commodity costs. But now that those costs have come down, a number of firms are on track to regain their lost profits. Cramer’s been looking for stocks that not only benefit from this trend but also work in a recession. Because if the talk is true, that’s just where we’re headed.
Becton Dickinson [BDX 73.31 0.95 (+1.31%) ] makes medical equipment from syringes and needles to infection systems and lab analyzers, just the type of equipment hospitals need regardless of record declines on the Dow. And BDX uses oil-based resin to make many of its products, an expense that jumped $20 million from 2007 to 2008. Back before the commodity decline, the company expected resin costs to jump another $20 million through 2009 based on $125 oil. But now that the price per barrel is down to $74, BDX could net more profit than expected, and that might send the stock higher.
This is a longer-term play, though. The lower costs won’t reach BDX’s bottom line for three to five months because at last report the company had three to four months worth of resin inventory. So think of BDX for 2009. Cramer did say, though, that the change in costs might mean an increase in 2009 guidance when BDX reports its fiscal fourth quarter on Nov. 5.
And Cramer expects good numbers from that report – the company’s beaten earnings every quarter for over a year. BDX is a seller of staple medical supplies, and it’s a market leader in most of the products it sells. So overall this is a consistent performer no matter which direction the market’s headed, and the lower costs make it even more attractive.
While price-to-earnings multiples haven’t worked for a lot of stocks in this market – who can trust projected earnings right now? – PEs do work for names not so sensitive to the economy. So BDX 14.4 multiple on next year’s conservative earnings estimate of $4.93 a share (remember: analysts are concerned about costs) can be trusted.
Given that BDX is the type of stock investors flock to in a downturn, Cramer said it’s not unlikely that multiple could climb to 18 during a recession. If that happens, then next year BDX will be worth $89, a 23% jump from present levels.
Durchsuchen
Becton, Dickinson and Company - US Medtechwert
